AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01002248
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
Trial: NCT00260260
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04135313
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m2 iv day 1
Trial: NCT00063310
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04544059
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 \[capped at 2.0 mg\], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
Trial: NCT02541409
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Direct acting antiviral agent used for the treatment of hepatitis C
Trial: NCT02541409
Drug: Pegylated Interferon alfa-2a
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiviral agent used for the treatment of hepatitis C
Trial: NCT02541409
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
Trial: NCT02950038
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 560 mg given by mouth daily in a 28 day cycle.
Trial: NCT02950038
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg/kg by vein beginning with Cycle 2 on Days 1 and 15 of every 28 day cycle.
Trial: NCT00534417
Drug: fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant will be given at 500mg on Day 1 followed by 250 mg on Days 15 and 29, then 250mg every 28 days(Q28d).
Trial: NCT00142272
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03538691
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as tablets.
Trial: NCT00765817
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, twice a day, 10mcg
Trial: NCT00545935
Drug: Methylenblue-Amodiaquine (MB-AQ)
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ
Trial: NCT00545935
Drug: Methylenblue-Artesunate (MB-AS)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days
Trial: NCT00887510
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablet once daily for 6 weeks~Other Names:~HCTZ
Trial: NCT00887510
Drug: Trandolapril
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg tablet once daily for 6 weeks
Trial: NCT00545935
Drug: Artesunate-Amodiaquine (AS-AQ)
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.
Trial: NCT01635803
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
Trial: NCT01635803
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5mg ranibizumab administered by monthly interval for six months (6 injections).
Trial: NCT02253888
Drug: Ritonavir (RTV)
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02185456
Drug: 750 mg metronidazole/ 200 mg miconazole vaginal suppository
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.
Trial: NCT03964688
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vitamin C intravenous during hospitalization, after oral, total 6 weeks.
Trial: NCT00376766
Drug: levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02081560
Drug: Colistin
RxNorm normalized name: Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colistin i.v. three times daily as long a necessary for infection treatment
Trial: NCT04162795
Drug: Loratadine (Claritin, BAY76-2211)
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable tablet, oral, single dose
Trial: NCT02421588
Drug: Lurbinectedin (PM01183)
RxNorm normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00092963
Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day
DrugBank: Rizatriptan (DB00953)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02527174
Drug: Volasertib
RxNorm normalized name: Volasertib
DrugBank: Volasertib (DB12062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.
Trial: NCT02527174
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV daily on Days 1-3 of treatment protocol.
Trial: NCT02527174
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
Trial: NCT00320268
Drug: Quetiapine fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03955809
Drug: Ketamine 0.5
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: İntrarticular Ketamine 0.5 mg/kg + 0.9 Nacl Total Volume 20 ml
Trial: NCT03955809
Drug: Ketamine 1
RxNorm normalized name: ketamine 10 MG/ML
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: İntrarticular Ketamine 1 mg/kg + 0.9 NaCl Total Volume 20 ml
Trial: NCT02207400
Drug: Sodium bicarbonate and sodium fluoride
RxNorm normalized name: sodium bicarbonate / sodium fluoride
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride
Trial: NCT02207400
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparator toothpaste containing 1100 ppm fluoride as sodium fluoride
Trial: NCT02542137
Drug: Thymalfasin
RxNorm normalized name: Thymalfasin
DrugBank: Thymalfasin (DB04900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
Trial: NCT01305772
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose Panitumumab 9mg/kg IV (in the vein) prior to definitive therapy (surgery or radiation therapy). Two additional doses of panitumumab 9mg/kg IV may be given at weeks 1 \& 4 of RT alone or weeks 1 \& 4 of cisplatin/RT if they tolerated first dose of panitumumab.
Trial: NCT03971916
Drug: HBM9161(HL161BKN)
RxNorm normalized name: Immunoglobulin g1(238-alanine, 239-alanine), anti-(human fcrn receptor) (human monoclonal hl161bkn .gamma.1-chain), disulfide with human monoclonal hl161bkn .lambda.-chain, dimer
DrugBank: Batoclimab (DB16104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection; Single dose on Day 1
Trial: NCT02512172
Drug: Oral CC-486
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02512172
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00645372
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6
Trial: NCT00645372
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6
Trial: NCT04481763
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab is 200 mg iv. administered every 2 weeks for 3 cycles with radiotherapy ( 50gy, 25 times for 5weeks)
Trial: NCT01127594
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose level selection will proceed according to the modified Accelerated Titration Design. The starting dose will be TMZ 200mg/m2 x 0.09 BSA for the upper extremity and 200mg/m2 x 0.18 BSA for the lower extremity. We will enroll one-patient cohorts with dose doubling between cohorts until 1st occurrence of a ≥ CTC (Common Terminology Criteria) grade 2 adverse event. At that time, the present cohort and all future cohorts will be extended to enroll 3 to 6 patients.
Trial: NCT00519467
Drug: Chlorproguanil-dapsone-artesunate (CDA)
RxNorm normalized name: Artesunate
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00546169
Drug: Fibrinogen (human) + thrombin (human) (TachoSil)
RxNorm normalized name: fibrinogen / thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haemorrhages in cholecystectomy
Trial: NCT03197467
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
Trial: NCT02421588
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03827798
Drug: MAS825
RxNorm normalized name: MAS825
DrugBank: MAS825 (DB16452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c.
Trial: NCT03827798
Drug: Placebo to MAS825
DrugBank: MAS825 (DB16452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c.
Trial: NCT02204644
Drug: Flumatinib 600mg qd
RxNorm normalized name: Flumatinib
DrugBank: Flumatinib (DB11904)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02204644
Drug: Imatinib 400mg qd
RxNorm normalized name: imatinib 400 MG
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02763319
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab: Dose: 375 mg/m2 IV
Trial: NCT02763319
Drug: Tafasitamab
RxNorm normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)
Trial: NCT02763319
Drug: Bendamustine (BEN)
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00437476
Drug: PEG-IFNa 2a
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFNa 2a 180 mcg/week (48 weeks)
Trial: NCT00437476
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin 1-1.2 g/day (48 weeks)
Trial: NCT04733625
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single injection of Vitamin D (200000 I.U
Trial: NCT02113007
Drug: Rituximab plus Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
Trial: NCT03883776
Drug: Al18F-NOTA-octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One intravenous injection of 4 MBq/kg
Trial: NCT02579382
Drug: TDF
RxNorm normalized name: moxetumomab pasudotox-tdfk
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg tablets administered orally once daily
Trial: NCT02579382
Drug: Vesatolimod
RxNorm normalized name: Vesatolimod
DrugBank: Vesatolimod (DB12687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once a week (every 7 days) for 12 doses
Trial: NCT03091426
Drug: Omiganan
RxNorm normalized name: Omiganan
DrugBank: Omiganan (DB06610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omiganan 1%
Trial: NCT03091426
Drug: Omiganan
RxNorm normalized name: Omiganan
DrugBank: Omiganan (DB06610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omiganan 1.75%
Trial: NCT03091426
Drug: Omiganan
RxNorm normalized name: Omiganan
DrugBank: Omiganan (DB06610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omiganan 2.5%
Trial: NCT00152243
Drug: UFT (uracil, tegafur)
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: uracil-tegafur 360 mg per square meter per day orally 16 months
Trial: NCT04131582
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
Trial: NCT00003190
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00003190
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00003190
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00003190
Drug: valspodar
RxNorm normalized name: VALSPODAR
DrugBank: Valspodar (DB11869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01196377
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol
Trial: NCT00306410
Drug: colecalciferol
RxNorm normalized name: colecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02328482
Drug: Tehalose 30gr
RxNorm normalized name: Trehalose
DrugBank: Trehalose (DB12310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
Trial: NCT02706769
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medication contains blinded paracetamol
Trial: NCT02501161
Drug: insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
Trial: NCT02501161
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
Trial: NCT04027179
Drug: 0.12% chlorhexidine digluconate mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine digluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
Trial: NCT01054222
Drug: Fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
Trial: NCT01054222
Drug: Fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
Trial: NCT01973517
Drug: Feraheme
RxNorm normalized name: Feraheme
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients with relapsing remitting multiple sclerosis will be administered Feraheme 5mg/kg IV via slow push once and imaged under high-field MRI at least 24 hours following administration, to allow for adequate clearance of intravascular pharmaceutical.
Trial: NCT01973517
Drug: Gadolinium-based contrast
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with relapsing remitting multiple sclerosis will be administered gadolinium-based contrast at a dose of 0.1 mmol/kg IV once and imaged under high-field MRI immediately following administration.
Trial: NCT02797145
Drug: Digoxin dose-adjusted
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serum digoxin concentration : 0.5 to 0.9 nanogram/mL
Trial: NCT03513471
Drug: Dermatophagoides Farinae
RxNorm normalized name: Dermatophagoides farinae
DrugBank: Dermatophagoides farinae (DB10400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
Trial: NCT04307524
Drug: medical treatment in the form of combined hormonal contraception
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient will receive for three months daily without interruption, no pill-free interval drug names is Genera BAYERhealthcare
Trial: NCT04098796
Drug: Anti-PD-1 antibody
RxNorm normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab will be administered 200 mg intravenous drip, every 3 weeks. Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years.
Trial: NCT03336814
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of terlipressine
Trial: NCT00420953
Drug: Cordarone
RxNorm normalized name: Cordarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02634801
Drug: Fumaric Acid Esters
RxNorm normalized name: Fumaric acid monomethyl ester
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02634801
Drug: Ixekizumab
RxNorm normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT03091738
Drug: Ramelteon Pill
RxNorm normalized name: ramelteon Pill
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with compensated cirrhosis and insomnia will be provided ramelteon
Trial: NCT02456025
Drug: Topical tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.01% twice daily for one month
Trial: NCT02888990
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02478164
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03499106
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Capsule